Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GNTA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Autologous CD34+-enriched HSPCs Transduc | Glioblastoma Multiforme | Phase 1/2 · NCT03866109 | Terminated |
Also used in these trials (approved or third-party drugs, not GNTA's own candidates): Cabozantinib, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GNTA holds $28.1M in cash and short-term investments and burns about $1.7M/quarter from operations, an estimated runway of 49.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 9 · Low
Our existing cash and cash equivalents as of December 31, 2025, will enable us to fund our operating expenses and capital expenditure requirements at least until December 2027.20-F, Apr 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GNTA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNTA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →